^
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
toripalimab
Sensitive
:
A1
GlobeNewswire - 1 week - (New A1)
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab + CP-675206
Resistant
:
B
ESMO 2022 - 3 weeks - (New B)
EGFR wild-type
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
B
Cancer Med - 3 weeks - (New B)
ALK wild-type
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
B
Cancer Med - 3 weeks - (New B)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation + PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
alectinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression
Lung Non-Squamous Non-Small Cell Cancer
MEDI5752
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive
:
A1
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive
:
A1
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab-maly
Sensitive
:
A1
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
VC
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
EP
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
CaT
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GemVin
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GT
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GC
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
carboplatin + pemetrexed
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
GemCarbo
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
erlotinib
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive
:
A2
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
afatinib
Sensitive
:
A2